Ultragenyx Pharmaceutical...

NASDAQ: RARE · Real-Time Price · USD
29.68
0.67 (2.31%)
At close: Aug 15, 2025, 3:59 PM
29.87
0.62%
After-hours: Aug 15, 2025, 07:57 PM EDT

Ultragenyx Pharmaceutical Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
173.73M 213.58M 132.94M 307.58M
Short-Term Investments
436.3M 363.63M 614.82M 432.61M
Long-Term Investments
135M 199.9M 154.5M 293.86M
Other Long-Term Assets
62.68M 57.69M 10.7M 11.62M
Receivables
121.8M 73.39M 40.45M 28.43M
Inventory
45.01M 33.97M 26.77M 16.23M
Other Current Assets
40.29M 47.62M 68.93M n/a
Total Current Assets
817.12M 732.18M 883.9M 856.6M
Property-Plant & Equipment
265.93M 290.57M 285.69M 176.18M
Goodwill & Intangibles
222.72M 210.68M 204.51M 175.19M
Total Long-Term Assets
686.33M 758.83M 661.54M 665.79M
Total Assets
1.5B 1.49B 1.55B 1.52B
Account Payables
38.76M 42.11M 43.27M 17.14M
Deferred Revenue
n/a n/a 1.48M 7.61M
Short-Term Debt
10.3M n/a 11.78M 11.07M
Other Current Liabilities
151.23M 142.79M 113.96M 71.9M
Total Current Liabilities
344.15M 280.44M 261.21M 181.37M
Long-Term Debt
n/a n/a n/a 351.79M
Other Long-Term Liabilities
836.91M 904.59M 880.26M 1M
Total Long-Term Liabilities
897.01M 935.16M 931.74M 418.47M
Total Liabilities
1.24B 1.22B 1.19B 599.84M
Total Debt
910.01M 43.17M 31.59M 41.97M
Common Stock
92K 82K 70K 69K
Retained Earnings
-3.96B -3.39B -2.78B -2.07B
Comprehensive Income
-643K 647K -6.57M -1.4M
Shareholders Equity
255.3M 275.41M 352.49M 922.56M
Total Investments
571.3M 563.53M 620.35M 726.47M